Volume 10,Issue 3
A Study on the Long-Term Efficacy and Safety of Budesonide-Formoterol Versus Montelukast in the Treatment of Seasonal Asthma
Objective: To compare the long-term efficacy and safety of budesonide-formoterol and montelukast in patients with seasonal asthma. Methods: A total of 270 outpatient asthma patients with seasonal exacerbation characteristics were selected from our hospital from March 2022 to September 2025 and randomly divided into three groups (A, B, and C), with 90 patients in each group. All patients received asthma health education. Patients in Group A inhaled budesonide-formoterol inhalation powder, patients in Group B took oral montelukast sodium tablets, and patients in Group C did not use any asthma control medications but only used salbutamol aerosol for symptomatic treatment during acute exacerbations. All patients were followed up for more than 2 years, and ACT scores, lung function indicators, and safety were compared. Results: (1) The ACT scores of Groups A and B were higher than those before treatment at 3, 6, 12, and 30 months of treatment (P<0.05), and continued to increase with the prolongation of treatment time, while there was no significant change in Group C (P>0.05). When comparing between groups, the ACT scores of Groups A and B were higher than those of Group C at 3, 6, 12, and 30 months of treatment (P<0.05), and Group A was significantly higher than Group B at 6, 12, and 30 months (P<0.05). (2) The FEV1 and FEV1/FVC of Groups A and B were higher than those before treatment at 3, 6, 12, and 30 months of treatment (P<0.05), while there was no significant change in Group C (P>0.05). When comparing between groups, the FEV1/FVC of Groups A and B were higher than those of Group C at 3, 6, 12, and 30 months of treatment (P<0.05), and Group A was significantly higher than Group B at 6, 12, and 30 months (P<0.05). (3) During the treatment period, there was no significant difference in the incidence of adverse reactions between Group A and Group B (P > 0.05). During the follow-up period, Group C experienced a total of 15 cases of asthma exacerbation complicated by other conditions, including 14 cases of pulmonary infection and 1 case of respiratory failure. All patients improved after symptomatic treatment, and no deaths occurred due to complications. Conclusion: Implementing preventive treatment for patients with seasonal asthma is of utmost importance. Both budesonide-formoterol and montelukast therapies can effectively alleviate patients' symptoms and exhibit comparable safety profiles. However, budesonide-formoterol demonstrates superior performance in long-term symptom control and lung function improvement. Clinical decision-making should comprehensively consider the specific conditions and treatment responses of patients to develop suitable individualized treatment plans.
[1] Creticos PS, Gunaydin FE, Nolte H, et al., 2024, Allergen Immunotherapy: The Evidence Supporting the Efficacy and Safety of Subcutaneous Immunotherapy and Sublingual Forms of Immunotherapy for Allergic Rhinitis/Conjunctivitis and Asthma. Journal of Allergy and Clinical Immunology: In Practice, 12(6): 1415-1427.
[2] Douglass JA, Lodge C, Chan S, et al., 2022, Thunderstorm asthma in seasonal allergic rhinitis: The TAISAR study. Journal of Allergy and Clinical Immunology, 149(5): 1607-1616.
[3] Genis C, Tas D, Yılmaz D, et al., 2025, Unraveling the effects of smoking in asthmatic adolescents: clinical outcomes, spirometry findings, and risk analysis. European Journal of Pediatrics, 184(8): 481.
[4] Sobieraj DM, Weeda ER, Nguyen E, et al., 2018, Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis. JAMA, 319(14): 1485-1496.
[5] Laitano R, Calzetta L, Matino M, et al., 2024, Asthma management with triple ICS/LABA/LAMA combination to reduce the risk of exacerbation: an umbrella review compliant with the PRIOR statement. Expert Opinion on Pharmacotherapy, 25(8): 1071-1081.
[6] Rayner DG, Liu M, Chu AWL, et al., 2024, Leukotriene receptor antagonists as adjunctive therapy to antihistamines for urticaria: A systematic review and meta-analysis of randomized clinical trials. Journal of Allergy and Clinical Immunology, 154(4): 996-1007.
[7] Tian R, Yang Y, Liu L, et al., 2022, Seasonal distribution of inhaled allergens in allergic asthma patients with or without allergic rhinitis. Chinese Medical Journal (English Edition), 135(15): 1867-1869.
[8] Papadopoulos NG, Miligkos M, Xepapadaki P. A, 2022, Current Perspective on Allergic Asthma: From Mechanisms to Management. Handbook of Experimental Pharmacology, 268: 69-93.
[9] Miller RL, Grayson MH, Strothman K., 2021, Advances in Asthma: New Insights into Asthma's Natural History, Risk Factors, Underlying Mechanisms, and Clinical Management. Journal of Allergy and Clinical Immunology, 148(6): 1430-1441.
[10] Tiotiu A, Steiropoulos P, Novakova S, et al., 2025, Airway Remodeling in Asthma: Mechanisms, Diagnosis, Treatment, and Future Directions. Archivos de Bronconeumologia, 61(1): 31-40.
[11] Zhou X, Zhang P, Tan H, et al., 2023, Progress in the Diagnosis and Treatment of Difficult-to-Treat Asthma in Children. Therapeutic Advances in Respiratory Disease, 17: 17534666231213637.
[12] Reddel HK, Bacharier LB, Bateman ED, et al., 2022, Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes . American Journal of Respiratory and Critical Care Medicine, 205(1): 17-35.
[13] Rodriguez-Martinez CE, Sossa-Briceño MP, Castro-Rodriguez JA., 2018, Cost-Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review. Pharmacoeconomics, 36(10): 1165-1200.
[14] Kaplan A, FitzGerald JM, Buhl R, et al., 2020, Comparison of LAMA with LABA and LTRA as Add-On Therapies in Primary Care Asthma Management. NPJ Primary Care Respiratory Medicine, 30(1): 50.
[15] Cividini S, Sinha I, Donegan S, et al., 2023, Optimal Step-Up Treatments for Children with Uncontrolled Asthma: A Systematic Review and Network Meta-Analysis of Individual Participant Data. European Respiratory Journal, 62(6): 2301011.
[16] Kaplan A, FitzGerald JM, Buhl R, et al., 2020, Comparison of LAMA with LABA and LTRA as Add-On Therapies in Primary Care Asthma Management. NPJ Primary Care Respiratory Medicine, 30(1): 50.
[17] Cividini S, Sinha I, Donegan S, et al., 2023, Optimal Step-Up Treatments for Children with Uncontrolled Asthma: A Systematic Review and Network Meta-Analysis of Individual Participant Data. European Respiratory Journal, 62(6): 2301011.